Dynavax Provides Regulatory Update on Heplisav-B

BERKELEY, CA -- (Marketwired) -- 09/04/16 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration ' s (FDA) Center for Biologics Evaluation and Research has cancelled the scheduled November 16,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news